ZNTL has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ZNTL has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Short Percentage of Float is the percentage of shares shorted compared to the float.
Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.
For the Biotechnology subindustry, Zentalis Pharmaceuticals's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Zentalis Pharmaceuticals's Short Percentage of Float distribution charts can be found below:
* The bar in red indicates where Zentalis Pharmaceuticals's Short Percentage of Float falls into.
Kimberly Blackwell | director | C/O ZENTALIS PHARMACEUTICALS, LLC, 530 SEVENTH AVENUE, SUITE 2201, NEW YORK NY 10018 |
David Michael Johnson | director | C/O ZENTALIS PHARMACEUTICALS, LLC, 530 SEVENTH AVENUE, SUITE 2201, NEW YORK NY 10018 |
Carrie Brownstein | officer: Chief Medical Officer | 500 W. 5TH ST., SUITE 1200, AUSTIN TX 78701 |
Kevin D. Bunker | officer: Chief Operating Officer | C/O ZENTALIS PHARMACEUTICALS, INC., 530 SEVENTH AVENUE, SUITE 2201, NEW YORK NY 10018 |
Melissa B, Epperly | officer: Chief Financial Officer | C/O ZENTALIS PHARMACEUTICALS, INC., 530 SEVENTH AVENUE, SUITE 2201, NEW YORK NY 10018 |
Jan Skvarka | director | C/O TRILLIUM THERAPEUTICS INC., 2488 DUNWIN DRIVE, MISSISSAUGA A6 L5L 1J9 |
Cam Gallagher | director | 6042 CORNERSTONE CT. WEST, SUITE B, SAN DIEGO CA 92121 |
Diana Hausman | director | C/O ONCOTHYREON INC., 2601 FOURTH AVE, SUITE 500, SEATTLE WA 98121 |
Iris Roth | officer: Chief Operating Officer | C/O ZENTALIS PHARMACEUTICALS, INC., 530 SEVENTH AVENUE, SUITE 2201, NEW YORK NY 10018 |
Andrea Paul | officer: General Counsel | 65 HAYDEN AVENUE, 2ND FLOOR, LEXINGTON MA 02421 |
Anthony Y Sun | director, officer: President & CEO | C/O AISLING CAPITAL, 888 SEVENTH AVENUE, 30TH FLOOR, NEW YORK NY 10106 |
Alexis Pinto | officer: Chief Legal Officer | C/O ZENTALIS PHARMACEUTICALS, LLC, 530 SEVENTH AVENUE, SUITE 2201, NEW YORK NY 10018 |
Dimitris Voliotis | officer: SVP, Clinical Development | C/O ZENTALIS PHARMACEUTICALS, INC., 530 SEVENTH AVENUE, SUITE 2201, NEW YORK NY 10018 |
Enoch Kariuki | director | C/O ZENTALIS PHARMACEUTICALS, LLC, 530 SEVENTH AVENUE, SUITE 2201, NEW YORK NY 10018 |
Viking Global Investors Lp | 10 percent owner | 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901 |
From GuruFocus
By Stock market mentor Stock market mentor • 01-03-2023
By sperokesalga sperokesalga • 04-26-2023
By GuruFocus Research • 11-07-2023
By sperokesalga sperokesalga • 05-10-2023
By sperokesalga sperokesalga • 06-06-2023
By Business Wire Business Wire • 01-10-2023
By Marketwired • 09-01-2023
By sperokesalga sperokesalga • 02-13-2023
By GuruFocus Research • 09-14-2023
By PRNewswire PRNewswire • 12-29-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.